B. van der Holt

发表

Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome.

R. V. van Klaveren, M. Hoogeman, P. Levendag, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.

J. Aerts, B. van der Holt, C. H. van der Leest, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology

B. Hazenberg, P. Sonneveld, E. Vellenga, 2015, Haematologica.

Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma

Yi Li, Parantu K. Shah, Cheng Li, 2014, Leukemia.

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

H. Inoko, M. Labopin, I. Yakoub-Agha, 2016, Blood.

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

V. V. D. van der Velden, B. van der Holt, O. Legrand, 2021, Blood advances.

A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform

M. Smid, E. Wiemer, J. Martens, 2013, Clinical Cancer Research.

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.

G. Mulligan, H. Goldschmidt, G. Morgan, 2015, Blood.

Evaluation of CEM43 degrees CT90 thermal dose in superficial hyperthermia: a retrospective analysis.

J. van der Zee, G. V. van Rhoon, B. van der Holt, 2010, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

E. Wiemer, J. Verweij, E. de Jonge, 2015, British journal of clinical pharmacology.

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

E. Wiemer, J. Verweij, B. van der Holt, 2012, Clinical Cancer Research.

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

D. Hose, H. Goldschmidt, P. Sonneveld, 2013, Blood.

Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence

E. Hovig, P. Sonneveld, O. Myklebost, 2022, Leukemia.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

A. Hagenbeek, J. Radford, K. Ardeshna, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

W. M. Smit, M. Kersten, P. Sonneveld, 2010, Haematologica.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

M. Kersten, D. Hose, H. Goldschmidt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

H. Goldschmidt, P. Sonneveld, E. Vellenga, 2008, Haematologica.

Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer.

R. V. van Klaveren, P. Levendag, J. Prevost, 2010, International journal of radiation oncology, biology, physics.

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.

P. Sonneveld, B. van der Holt, H. Kluin-Nelemans, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.

B. van der Holt, S. Henzen‐Logmans, A. D. Krol, 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.

P. Sonneveld, B. van der Holt, B. Löwenberg, 2000, Haematologica.

18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study

R. Boellaard, H. D. de Vet, M. Heymans, 2021, The Journal of Nuclear Medicine.

Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

P. Sonneveld, E. van den Berg, B. van der Holt, 2004, Leukemia research.

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma

J. Baars, P. Sonneveld, E. Vellenga, 1999, British journal of haematology.

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2014, The Lancet. Oncology.

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

C. Seynaeve, J. Verweij, J. Beijnen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

M. Kersten, P. Sonneveld, B. van der Holt, 2011, Blood.

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

G. Castellani, H. Goldschmidt, P. Sonneveld, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Andrew P. Stubbs, R. Vernhout, M. J. van den Bent, 2016, Cancer research.

The Effect of Differentiation Grade of Cutaneous Squamous Cell Carcinoma on Excision Margins, Local Recurrence, Metastasis, and Patient Survival: A Retrospective Follow-Up Study

S. Hovius, B. van der Holt, M. D. den Bakker, 2015, Annals of plastic surgery.

Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants.

B. van der Holt, H. Spits, B. Löwenberg, 2003, Blood.

Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients

J. Kosterink, B. van der Holt, M. van den Berge, 2022, PloS one.

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

H. Goldschmidt, G. Morgan, P. Sonneveld, 2011, Haematologica.

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

W. M. Smit, M. Kersten, P. Sonneveld, 2008, Blood.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

J. Baars, P. Sonneveld, E. Vellenga, 2002, Blood.

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

H. Goldschmidt, P. Sonneveld, B. van der Holt, 2010, The Lancet. Oncology.

High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.

P. Sonneveld, B. van der Holt, F. Leebeek, 2009, Blood.

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.

P. Sonneveld, B. van der Holt, J. Janssen, 2009, Blood.

Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.

P. Sonneveld, B. van der Holt, H. Lokhorst, 2007, Haematologica.

Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features

R. Boellaard, H. D. de Vet, O. Hoekstra, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations

M. Kersten, B. van der Holt, P. Kluin, 2014, Blood Cancer Journal.

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.

S. Sleijfer, E. Wiemer, B. van der Holt, 2016, European journal of cancer.

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).

M. Kersten, D. de Jong, F. d'Amore, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.

P. Sonneveld, B. van der Holt, R. V. van Schaik, 2007, The Journal of antimicrobial chemotherapy.

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.

P. Sonneveld, B. van der Holt, M. V. van Oers, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non‐selected haematological population of patients

B. van der Holt, J. Gratama, M. Levin, 2004, Vox sanguinis.

Visual scoring versus histogram subtraction of in vivo binding of immunoglobulins against platelets after transfusion

B. van der Holt, J. Gratama, M. Levin, 2004, Cytometry. Part B, Clinical cytometry.

Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia.

B. van der Holt, C. Majoie, S. Middeldorp, 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features

R. Boellaard, H. D. de Vet, O. Hoekstra, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

M. Kersten, H. Goldschmidt, P. Sonneveld, 2014, Haematologica.

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile

P. Sonneveld, N. Munshi, V. V. D. van der Velden, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement.

P. Sonneveld, B. van der Holt, P. Huijgens, 2015, Health policy.

Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic stem cell transplantation

C. Boucher, B. van der Holt, J. Gratama, 2001, British journal of haematology.

Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation

B. van der Holt, C. Lamers, J. Cornelissen, 2018, Bone Marrow Transplantation.

Monitoring cytomegalovirus IE‐1 and pp65‐specific CD4+ and CD8+ T‐cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations

B. van der Holt, B. Löwenberg, H. Niesters, 2008, Cytometry. Part B, Clinical cytometry.

The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed

H. Putter, B. van der Holt, J. Passweg, 2021, Cancer medicine.

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

V. V. D. van der Velden, J. te Marvelde, B. van der Holt, 2019, Leukemia research.

Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.

M. J. van den Bent, B. van der Holt, P. S. Sillevis Smitt, 2003, Brain : a journal of neurology.

A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.

B. van der Holt, J. Gratama, B. Löwenberg, 2005, Experimental hematology.

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

B. van der Holt, J. Gratama, A. Osterhaus, 2002, Blood.

Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status

I. Yakoub-Agha, D. Blaise, M. Mohty, 2020, Bone Marrow Transplantation.

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

B. van der Holt, A. Osterhaus, B. Löwenberg, 2001, Blood.

Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients

B. van der Holt, E. Wils, J. Gratama, 2011, Haematologica.

Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study

B. van der Holt, J. Cornelissen, E. Braakman, 2014, Haematologica.

P. Sonneveld, E. Vellenga, B. van der Holt, 2007, Annals of Hematology.

p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.

L. Looijenga, B. van der Holt, D. D. de Rooij, 1995, British Journal of Cancer.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.

J. Baars, P. Sonneveld, B. van der Holt, 2009, Blood.

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

P. Sonneveld, E. Vellenga, B. van der Holt, 2005, Blood.

P. Sonneveld, E. Wiemer, R. Pieters, 2001, Blood.

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

E. Schuuring, B. van der Holt, H. Kluin-Nelemans, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.

M. J. van den Bent, M. Taphoorn, J. Reijneveld, 2015, European journal of cancer.

Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation

B. van der Holt, S. Middeldorp, B. Biemond, 2013, Thrombosis and Haemostasis.

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human

H. Hoogsteden, J. Aerts, B. van der Holt, 2017, Clinical Cancer Research.

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.

M. Kersten, P. Sonneveld, B. van der Holt, 2012, Blood.

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

P. Sonneveld, M. Kersten, G. Mulligan, 2010, Blood.

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

W. M. Smit, B. van der Holt, G. Verhoef, 2006, Annals of Hematology.

Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates

M. D. Den Boer, B. van der Holt, J. Boer, 2015, Haematologica.

CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies

M. J. van den Bent, B. van der Holt, J. Gratama, 2007, Neurology.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

M. Kersten, D. Hose, H. Goldschmidt, 2018, Leukemia.

Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.

P. Sonneveld, B. van der Holt, M. V. van Vliet, 2020, Blood advances.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

R. Vernhout, M. J. van den Bent, M. Taphoorn, 2014, The Lancet. Oncology.

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

D. Hose, H. Goldschmidt, A. Jauch, 2012, Blood.

MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

P. Sonneveld, R. Pieters, B. van der Holt, 1997, British journal of haematology.

The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B‐cell lymphomas

P. Sonneveld, B. van der Holt, R. Delwel, 2011, European journal of haematology.

Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials.

D. de Jong, P. Sonneveld, B. van der Holt, 2011, Clinical lymphoma, myeloma & leukemia.

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.

P. Sonneveld, E. Vellenga, B. van der Holt, 2007, Haematologica.

A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.

M. Höglund, B. van der Holt, B. Löwenberg, 2003, Experimental hematology.

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

P. Sonneveld, B. van der Holt, G. Ossenkoppele, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of patient enrollment in oncology phase I clinical trials.

E. Wiemer, J. Verweij, B. van der Holt, 2013, The oncologist.

Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study

B. Heijmen, B. van der Holt, D. V. van Gent, 2018, BMJ Open.

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

W. M. Smit, B. van der Holt, N. Thielen, 2013, European journal of cancer.

Reduction of interlaboratory variability in flow cytometric immunophenotyping by standardization of instrument set-up and calibration, and standard list mode data analysis.

P Reinders, J W Gratama, J Kraan, 1997, Cytometry.

Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to rituximab treatment in ITP patients.

B. van der Holt, J. Zwaginga, M. Schipperus, 2017, Blood.

Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors.

B. van der Holt, D. Deeren, J. Cornelissen, 2019, Blood.

Translating in vitro prediction of cytotoxic T cell alloreactivity to hematopoietic stem cell transplantation outcome.

F. Claas, B. van der Holt, P. A. von dem Borne, 2014, Transplant immunology.

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial

B. van der Holt, J. Cornelissen, M. Hazenberg, 2022, Blood advances.

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

M. Dimopoulos, P. Sonneveld, M. Boccadoro, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

P. Sonneveld, V. V. D. van der Velden, M. Boccadoro, 2021, Blood Cancer Journal.

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud

U. Mellqvist, M. Dimopoulos, P. Sonneveld, 2020, The Lancet. Haematology.

Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations

B. van der Holt, J. Calis, J. Cornelissen, 2019, Front. Immunol..

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry

P. Sonneveld, B. van der Holt, S. Croockewit, 2022, HemaSphere.

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

S. Sleijfer, R. Vernhout, M. J. van den Bent, 2015, British Journal of Cancer.

Analysis of factors contributing to the formation of mononuclear cell aggregates ("escapees") in flow cytometric immunophenotyping.

B. van der Holt, J. Gratama, J. V. D. van de Winkel, 1997, Cytometry.

Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.

S. Sleijfer, A. Eggermont, B. van der Holt, 2008, Psychosomatics.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

P. Sonneveld, J. Miguel, M. Boccadoro, 2013, Haematologica.

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy

R. Neuwirth, G. Mulligan, H. Goldschmidt, 2011, Haematologica.

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Dave J. Bekers, Gabriel P. Krestin, Patrick Schöffski, 2012, PloS one.

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma

P. Sonneveld, B. van der Holt, G. Verhoef, 2007, British journal of haematology.

18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma

R. Boellaard, H. D. de Vet, O. Hoekstra, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group.

A. Hagenbeek, M. J. van den Bent, B. van der Holt, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

U. Mellqvist, P. Sonneveld, B. van der Holt, 2016, Blood.

Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients

Claudia Schoch, Walter Knapp, Alberto Orfao, 2001, British journal of haematology.

Stereotactic body radiotherapy using real-time tumor tracking in octogenarians with non-small cell lung cancer.

R. V. van Klaveren, J. Nuyttens, N. C. van der Voort van Zyp, 2010, Lung cancer.

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study

B. van der Holt, J. Janssen, J. Cornelissen, 2018, Transfusion.

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status

S. Sleijfer, A. Eggermont, B. van der Holt, 2008, Psychiatry and clinical neurosciences.

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

S. Sleijfer, A. Eggermont, B. van der Holt, 2007, Neuropsychobiology.

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma.

S. Sleijfer, A. Eggermont, B. van der Holt, 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

M. J. van den Bent, W. Dinjens, T. Postma, 2011, Neuro-oncology.

Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.

S. Sleijfer, A. Eggermont, B. van der Holt, 2007, Neuropsychobiology.

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

S. Sleijfer, A. Eggermont, B. van der Holt, 2008, Amino Acids.

The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab

R. Vernhout, M. J. van den Bent, B. van der Holt, 2022, Neuro-oncology advances.

Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial

R. Vernhout, M. J. van den Bent, B. van der Holt, 2017, Neuro-oncology.

CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

E. Wiemer, J. Verweij, B. van der Holt, 2013, Clinical Cancer Research.

Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.

P. Sonneveld, B. van der Holt, J. Doorduijn, 2004, Haematologica.

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

P. Sonneveld, E. Vellenga, B. van der Holt, 2010, Blood.

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.

M. Kersten, A. Palumbo, P. Sonneveld, 2015, Blood.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

M. Kersten, P. Sonneveld, E. Vellenga, 2018, The Lancet. Haematology.

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial

P. Sonneveld, B. van der Holt, M. Delforge, 2022, Haematologica.

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

M. Kersten, A. Palumbo, P. Sonneveld, 2020, HemaSphere.

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial

P. Sonneveld, E. van den Berg, B. van der Holt, 2007, British journal of haematology.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

H. Goldschmidt, A. Palumbo, P. Sonneveld, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma

P. Sonneveld, W. Gregory, B. van der Holt, 2021, Cancers.

Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial

B. van der Holt, D. Hesselink, R. V. van Schaik, 2021, Clinical pharmacology and therapeutics.

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

B. van der Holt, R. van der Griend, E. V. van Pampus, 2015, Haematologica.

U. Mellqvist, P. Sonneveld, B. van der Holt, 2019, Haematologica.

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.

P. Sonneveld, B. van der Holt, C. U. Uyl‐de Groot, 2004, European journal of cancer.

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

P. Sonneveld, R. Benjamin, B. van der Holt, 2019, Blood.

Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

B. van der Holt, C. Lamers, C. V. van Bergen, 2019, HemaSphere.

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

P. Sonneveld, B. Pégourié, M. Boccadoro, 2013, Haematologica.

In vivo fluorescence kinetics and localisation of aluminum phthalocyanine disulphonate in an autologous tumour model.

J. M. Nauta, J. Roodenburg, M. Witjes, 1996, British Journal of Cancer.

Clinical introduction of Monte Carlo treatment planning: a different prescription dose for non-small cell lung cancer according to tumor location and size.

Steven van de Water, M. Hoogeman, P. Levendag, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study.

R. V. van Klaveren, M. Hoogeman, J. Aerts, 2015, International journal of radiation oncology, biology, physics.

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

M. Kersten, P. Sonneveld, B. van der Holt, 2015, Haematologica.

Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities

U. Mellqvist, P. Sonneveld, B. van der Holt, 2020, Leukemia.

Music to prevent deliriUm during neuroSurgerY (MUSYC): a single-centre, prospective randomised controlled trial

S. Kushner, B. van der Holt, C. Dirven, 2023, BMJ open.

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

M. Kersten, A. Palumbo, P. Sonneveld, 2019, Haematologica.

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial.

M. Kersten, A. Palumbo, P. Sonneveld, 2016, Haematologica.